Galderma Group N (GALD) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.061x

Based on the latest financial reports, Galderma Group N (GALD) has a cash flow conversion efficiency ratio of 0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF475.06 Million ≈ $600.61 Million USD) by net assets (CHF7.73 Billion ≈ $9.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GALD market cap overview for the company's overall valuation and market capitalisation.

Galderma Group N - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how Galderma Group N's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Galderma Group N Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Galderma Group N ranked by their cash flow conversion efficiency. Explore GALD cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Hanwha Aerospace Co Ltd KO:012450	-0.071x
Lonza Group AG SW:LONN	0.081x
KOMATSU LTD. SPONS. ADR 1 F:KOMA	N/A
Endesa SA MC:ELE	0.108x
OTP Bank Nyrt BUD:OTP	-0.124x
PT BK CE.AS.ADR/25 RP625 F:BZG	0.041x
Rocket Lab USA Inc. NASDAQ:RKLB	-0.022x
AHOLD DELHAI.ADR16 EO-25 F:AHOD	0.121x

Annual Cash Flow Conversion Efficiency for Galderma Group N (2021–2024)

The table below shows the annual cash flow conversion efficiency of Galderma Group N from 2021 to 2024. View latest Galderma Group N stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF7.79 Billion ≈ $9.85 Billion	CHF429.77 Million ≈ $543.34 Million	0.055x	+67.62%
2023-12-31	CHF4.52 Billion ≈ $5.71 Billion	CHF148.64 Million ≈ $187.92 Million	0.033x	+28.01%
2022-12-31	CHF4.13 Billion ≈ $5.23 Billion	CHF106.30 Million ≈ $134.39 Million	0.026x	-40.45%
2021-12-31	CHF4.14 Billion ≈ $5.24 Billion	CHF178.92 Million ≈ $226.21 Million	0.043x	--

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$45.51 Billion

CHF36.00 Billion CHF

Market Cap Rank

#746 Global

#12 in Switzerland

Share Price

CHF153.30

Change (1 day)

-1.48%

52-Week Range

CHF134.70 - CHF185.80

All Time High

CHF185.80